Appeal No. 2002-0427 Page 2
Application No. 08/179,656
The examiner relies on the following references:
Tischer et al. (Tischer), ”Vascular endothelial growth factor: A new member of
the platelet-derived growth factor gene family,” Biochemical and Biophysical
Research Communication, Vol. 165, No. 3, pp. 1198-1206 (1989)
Bowie et al. (Bowie), ”Deciphering the Message in Protein Sequences:
Tolerance to Amino Acid Substitutions,” Science, Vol. 247, pp. 1306-1310 (1990)
Wells, “Additivity of Mutational Effects in Proteins,” Biochemistry, Vol. 29, No. 37
pp. 8509-8517 (1990)
Robinson, “Growth factors in wound healing,” TibTech, Vol. 10, pp. 2-3 (1992)
Meyer-Ingold, “Wound therapy: growth factors as agents to promote healing”
TibTech, Vol. 11, pp. 387-392 (1993)
Pilbeam et al. (Pilbeam), “Comparison of the Effects of Various Lengths of
Synthetic Human Parathyroid Hormone-Related Peptide (hPTHrP) of Malignancy
on Bone Resorption and Formation in Organ Culture,” Bone, Vol. 14, pp. 717-720
(1993)
Daniel et al. (Daniel), ”Mapping of Linear Antigenic Sites on the S Glycoprotein of
a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of
Nine Prediction Algorithms Fails to Identify Relevant Epitopes and Peptide
Immunogencity Is Drastically Influenced by the Nature of the Protein Carrier,”
Virology, Vol. 202, pp. 540-549 (1994)
Callard et al. (Callard), The Cytokine FactsBook, p. 31 (1994)
Ngo et al. (Ngo), Computational Complexity, Protein Structure Prediction, and the
Levinthal Paradox,” The Protein Folding Problem and Tertiary Sturcture
Prediction, pp. 491-495 (1994)
Claims 1, 3, 5, and 23-26 stand rejected under 35 U.S.C. § 112, first
paragraph, as nonenabled.
Claims 1, 3, 5, and 23-26 stand rejected under 35 U.S.C. § 112, first
paragraph, as lacking an adequate written description in the specification.
We affirm the written description rejection and do not reach the
enablement rejection.
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 Next
Last modified: November 3, 2007